Recent developments include strategic acquisitions expanding the defense technology portfolio, leadership changes, and new commercial agreements.

• BiomX acquired 60% of DFSL, a LADAR-based detection systems company, expanding its defense technology offerings [N1].
• The company completed the acquisition of Zorronet, an AI-powered security platform company, to enhance its autonomous surveillance capabilities [N2].
• BiomX appointed Michael Oster as CEO and David Rokach as CFO in early 2026, bringing experienced leadership to the company [N4].
• The company added Dr. Ehud (Udi) Levi, former Deputy Head of Mossad, to its advisory board to guide strategic opportunities in security and defense [N3].
• BiomX signed a framework supply agreement with Israel Railways for AI-powered animal detection and deterrence alert stations following a successful pilot program [N2].
• The company received a notice from NYSE American regarding non-compliance with listing standards related to stockholders’ equity and submitted a compliance plan [S1].

BiomX’s acquisitions of DFSL and Zorronet have expanded its technology portfolio and customer base in the defense sector, positioning it to leverage growing demand for counter-drone and AI-powered surveillance solutions. The company’s recent leadership appointments bring experience in corporate strategy and capital markets, potentially enhancing operational execution. Successful integration of subsidiaries and execution of contracts with key customers such as Elbit Systems and Rafael Advanced Defense Systems could strengthen its market presence. The framework agreement with Israel Railways demonstrates commercial traction in critical infrastructure applications.

BiomX faces significant risks including customer concentration, with a substantial portion of revenues dependent on a few key defense contractors and government agencies. The company’s financial position shows net losses and limited liquidity, with potential dilution from outstanding convertible securities and warrants. Regulatory compliance, including export controls and NYSE American listing standards, presents ongoing challenges. The company’s management has limited experience in operating a U.S. public defense technology company, and competition from larger, established firms may limit growth. Integration risks and performance-based earnout obligations from acquisitions add financial and operational uncertainty.

BiomX’s competitive position is supported by proprietary technologies in LADAR detection and AI-driven surveillance software, established relationships with key defense contractors and government agencies, and operational deployments in sensitive defense environments. Its subsidiaries’ integration of advanced sensor technologies with autonomous response capabilities addresses growing market demands in counter-UAS and critical infrastructure protection. However, the company faces competition from larger, well-resourced defense contractors and technology firms, and its intellectual property protection relies heavily on trade secrets and contractual safeguards rather than extensive patent portfolios.

• Customer Concentration Risk: A significant portion of revenues is derived from a limited number of key customers, including Elbit Systems and Rafael Advanced Defense Systems. Loss or reduction of business from these customers could materially harm financial results.
• Regulatory and Compliance Risks: The company is subject to Israeli and U.S. defense export control laws, NYSE American listing standards, and SEC reporting requirements. Non-compliance could result in penalties, delisting, or operational restrictions.
• Financial and Liquidity Risks: The company reported net losses and limited cash resources as of March 31, 2026. Outstanding convertible notes, warrants, and earnout obligations may dilute shareholders and strain liquidity.
• Competition and Market Risks: BiomX competes with large defense contractors and specialized technology firms with greater resources. Rapid technological change and evolving customer requirements may impact competitiveness.
• Management and Execution Risks: The current management team has limited experience operating a U.S. public company in the defense technology sector, which may affect execution of strategic plans and compliance obligations.

• BiomX Inc. operates as a holding company with three principal subsidiaries: DFSL (60% owned), Zorronet (wholly owned), and X Security & Defense (wholly owned).
• DFSL develops proprietary LADAR-based detection systems for counter-drone and aerial threat detection, with manufacturing and assembly in Israel.
• Zorronet develops AI-powered computer vision and autonomous surveillance software platforms for defense, homeland security, and critical infrastructure protection, operationally deployed at Israeli Defense Forces bases and other critical sites.
• X Security & Defense focuses on security, defense, and first-response technologies and has not yet commenced commercial operations.
• The company’s products are marketed through direct government and military sales, co-development with prime defense contractors, distribution agreements, and project-based engagements.
• Key customers include Elbit Systems Ltd., Rafael Advanced Defense Systems, Israel Defense Forces, Israel Railways, and other government and infrastructure entities.
• Zorronet’s platform is installed in multiple IDF control rooms and manages thousands of devices across various facilities.
• The company acquired Zorronet in April 2026 and DFSL in April 2026, expanding its defense technology portfolio.
• Zorronet’s acquisition included a performance-based earnout obligation payable by March 31, 2027, based on revenue or EBITDA.
• The company appointed Michael Oster as CEO in March 2026 and David Rokach as CFO in February 2026, both with extensive leadership experience.
• The company received a notice from NYSE American in March 2026 for non-compliance with listing standards related to stockholders’ equity and submitted a compliance plan in April 2026.
• As of March 31, 2026, the company had cash and equivalents of $1.168 million, current assets of $3.043 million, current liabilities of $2.447 million, a current ratio of 1.24, and a net loss of $19.14 million for the quarter.
• The company ceased all clinical trials and product candidate development as of December 2025 and transitioned to a defense technology focus.
• The company’s workforce is primarily in its subsidiaries in Israel, with no employees at the parent company level.
• Zorronet signed a framework supply agreement with Israel Railways in April 2026 to supply AI-powered animal detection and deterrence alert stations following a successful pilot.
• The company’s subsidiaries face competition from large defense contractors and specialized technology firms with greater resources.
• The company’s subsidiaries are subject to Israeli and U.S. export control laws, which may affect international sales.
• The company’s financials show significant net losses and limited liquidity, with risks related to dilution from convertible securities and warrants.
• The company’s business depends on a limited number of key customers, with concentration risk particularly in Zorronet’s contracts with Elbit Systems and Rafael Advanced Defense Systems.
• The company’s management team has limited experience operating a U.S. public company in the defense technology sector.
• The company’s subsidiaries rely on proprietary technology, trade secrets, and contractual protections for intellectual property.
• The company’s subsidiaries’ revenues are subject to timing and political considerations related to government and prime contractor procurement cycles.